Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatment
- 1 July 2009
- journal article
- editorial
- Published by Elsevier BV in Free Radical Biology & Medicine
- Vol. 47 (1), 27-29
- https://doi.org/10.1016/j.freeradbiomed.2009.04.001
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effectsFree Radical Biology & Medicine, 2009
- Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic DrugsCancer Research, 2008
- Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Phase I clinical trial of i.v. ascorbic acid in advanced malignancyAnnals of Oncology, 2008
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- New Concepts in the Biology and Biochemistry of Ascorbic AcidThe New England Journal of Medicine, 1986
- High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior ChemotherapyThe New England Journal of Medicine, 1985
- Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced CancerThe New England Journal of Medicine, 1979
- The orthomolecular treatment of cancer: III. Reticulum cell sarcoma: Double complete regression induced by high-dose ascorbic acid therapyChemico-Biological Interactions, 1975
- ASCORBIC ACID, CELL PROLIFERATION, AND CANCERThe Lancet, 1972